Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07521046 · ClinicalTrials.gov registry record · Phase 1
Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)
A Phase 1 study, sponsored by University of Utah.
- Not yet
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT07521046 is a Phase 1 study that has not yet begun recruiting, run by University of Utah. The registered enrollment target is 15 participants.
The verdict
NCT07521046, a Phase 1 study, has not yet begun recruiting, sponsored by University of Utah.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to learn if the study drug ropeginterferon alfa- 2b added to, standard of care, ruxolitinib is safe and effective in treating patients with Myelofibrosis.
Interventions
- DRUG Ruxolitinib
- DRUG ropeginterferon alfa- 2b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-08 |
| Est. Completion | 2030-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07521046
The ClinicalTrials.gov registry entry for NCT07521046 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT07521046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07521046 about?
NCT07521046 is a clinical study titled "Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)". The purpose of this clinical trial is to learn if the study drug ropeginterferon alfa- 2b added to, standard of care, ruxolitinib is safe and effective in treating patients with Myelofibrosis.
What is the current status of trial NCT07521046?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2026-08. Estimated completion is 2030-08.
What interventions are being tested in trial NCT07521046?
The interventions under investigation include: Ruxolitinib (DRUG), ropeginterferon alfa- 2b (DRUG).
Who is sponsoring clinical trial NCT07521046?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.